Voyager Therapeutics

Voyager Therapeutics
https://voyagertherapeutics.com/

Field:
Genetic Engineering

Focus:
Brain

Type: Public Corporation
Founded: 2014
HQ: United States

Leadership
Michael Higgins
CEO
Financial Performance


Funding


Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2014
45M USD
Series A
2015
30M USD
Corporate Equity
2015
Equity
/ 60.0M USD
U.S. SEC Form D
60M USD
Series B
2015
70M USD
Post-IPO Equity
Known Investors
Name
Type
HQ
Other Relevant Investments
Bain Capital Public Equity
Asset Management
United States
Casdin Capital
Venture Capital
United States
Editas Medicine
PFM Health Sciences
Venture Capital
United States
Sanofi Genzyme
Corporation
United States
Third Rock Ventures
Venture Capital
United States
Editas Medicine
Wellington Management
Investment Bank
United States
Spark Therapeutics
Magic Leap
CRISPR Therapeutics
*More data available at: [CB Insights] [CrunchBase] [PitchBook]
Related
News